Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Hovione announced today that it held on June 8th the official groundbreaking for the expansion of its New Jersey facility in East Windsor, USA
Hovione invests over €30m in the USA
Irish Examiner, 21 june 2021
Its lead single-use nasal dry powder device now available for commercial partnerships
Hovione is expanding its scientific know-how and industrial production capabilities on a variety of technologies to widen its ability to provide customized solutions for advanced APIs (aAPI™).
Hovione offers simple, patented and globally competitive dry powder inhalers – Disposable, Capsule, Blister and Large Dose DPIs – which are available for fully integrated turn-key development with formulation and for licensing.
Hovione is Growing
Google Chrome
Safari
Firefox
Edge